Your browser doesn't support javascript.
loading
Renin as a Biomarker to Guide Medical Treatment in Primary Aldosteronism Patients. Findings from the SPAIN-ALDO Registry.
Parra Ramírez, Paola; Martín Rojas-Marcos, Patricia; Paja Fano, Miguel; González-Boillos, Margarita; Pascual-Corrales, Eider; García Cano, Ana María; Ruiz-Sanchez, Jorge Gabriel; Vicente Delgado, Almudena; Gómez Hoyos, Emilia; Ferreira, Rui; García Sanz, Iñigo; Recasens Sala, Mònica; Barahona San Millan, Rebeca; Picón César, María José; Díaz Guardiola, Patricia; Perdomo, Carolina M; Manjón-Miguélez, Laura; Rebollo Román, Ángel; Robles Lázaro, Cristina; Morales-Ruiz, Manuel; Calatayud, María; Andree Furio Collao, Simone; Meneses, Diego; Sampedro-Nuñez, Miguel Antonio; Mena Ribas, Elena; Sanmartín Sánchez, Alicia; Gonzalvo Diaz, Cesar; Lamas, Cristina; Guerrero-Vázquez, Raquel; Del Castillo Tous, María; Serrano Gotarredona, Joaquín; Michalopoulou Alevras, Theodora; Tenés Rodrigo, Susana; Roa Chamorro, Ricardo; Jaen Aguila, Fernando; Moya Mateo, Eva María; Hanzu, Felicia A; Araujo-Castro, Marta.
Affiliation
  • Parra Ramírez P; Endocrinology and Nutrition Department, Hospital Universitario La Paz, Madrid, Spain.
  • Martín Rojas-Marcos P; Endocrinology and Nutrition Department, Hospital Universitario La Paz, Madrid, Spain.
  • Paja Fano M; Endocrinology and Nutrition Department, OSI Bilbao-Basurto, Hospital Universitario de Basurto, Bilbao, Spain.
  • González-Boillos M; University of the Basque Country UPC/EHU, Bilbao, Spain.
  • Pascual-Corrales E; Endocrinology and Nutrition Department, Hospital Universitario de Castellón, Castelló de la Plana, Castellón, Spain.
  • García Cano AM; Endocrinology and Nutrition Department, Hospital Universitario Ramón y Cajal, Colmenar Viejo Street km 9, 28034, Madrid, Spain.
  • Ruiz-Sanchez JG; Instituto de Investigación Biomédica Ramón y Cajal (IRYCIS), Madrid, Spain.
  • Vicente Delgado A; Biochemistry Department, Hospital Universitario Ramón y Cajal, Madrid, Spain.
  • Gómez Hoyos E; Endocrinology and Nutrition Department, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain.
  • Ferreira R; Endocrinology and Nutrition Department, Hospital Universitario de Toledo, Toledo, Spain.
  • García Sanz I; Endocrinology and Nutrition Department, Hospital Universitario de Valladolid, Valladolid, Spain.
  • Recasens Sala M; Endocrinology and Nutrition Department, Hospital Universitario Rey Juan Carlos, Madrid, Spain.
  • Barahona San Millan R; General and Digestive Surgery Department, Hospital Universitario de La Princesa, Madrid, Spain.
  • Picón César MJ; Endocrinology and Nutrition Department, Hospital De Girona Doctor Josep Trueta, Girona, Spain.
  • Díaz Guardiola P; Endocrinology and Nutrition Department, Hospital De Girona Doctor Josep Trueta, Girona, Spain.
  • Perdomo CM; Endocrinology and Nutrition Department, Hospital Universitario Virgen de la Victoria de Málaga, IBIMA Malaga, Málaga, Spain.
  • Manjón-Miguélez L; CIBEROBN, Madrid, Spain.
  • Rebollo Román Á; Endocrinology and Nutrition Department, Hospital Universitario Infanta Sofía, Madrid, Spain.
  • Robles Lázaro C; Endocrinology and Nutrition Department, Clínica Universidad de Navarra, Pamplona, Spain.
  • Morales-Ruiz M; Endocrinology and Nutrition Department, Hospital Universitario Central de Asturias, Oviedo, Spain.
  • Calatayud M; Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Oviedo, Spain.
  • Andree Furio Collao S; Endocrinology and Nutrition Department, Hospital Reina Sofía, Córdoba, Spain.
  • Meneses D; Endocrinology and Nutrition Department, Hospital Clínico Universitario de Salamanca, Salamanca, Spain.
  • Sampedro-Nuñez MA; Biochemistry and Molecular Genetics Department-CDB, Hospital Clinic, IDIBAPS, CIBERehd, Barcelona, Spain.
  • Mena Ribas E; Endocrinology and Nutrition Department, Hospital Doce de Octubre, Madrid, Spain.
  • Sanmartín Sánchez A; Endocrinology and Nutrition Department, Hospital Doce de Octubre, Madrid, Spain.
  • Gonzalvo Diaz C; Endocrinology and Nutrition Department, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain.
  • Lamas C; Endocrinology and Nutrition Department, Hospital Universitario La Princesa Madrid, Madrid, Spain.
  • Guerrero-Vázquez R; Endocrinology and Nutrition Department, Hospital Universitario Son Espases, Palma, Islas Baleares, Spain.
  • Del Castillo Tous M; Endocrinology and Nutrition Department, Hospital Universitario Son Espases, Palma, Islas Baleares, Spain.
  • Serrano Gotarredona J; Endocrinology and Nutrition Department, Complejo Hospitalario Universitario de Albacete, Albacete, Spain.
  • Michalopoulou Alevras T; Endocrinology and Nutrition Department, Complejo Hospitalario Universitario de Albacete, Albacete, Spain.
  • Tenés Rodrigo S; Endocrinology and Nutrition Department, Hospital Universitario Virgen Macarena, Sevilla, Spain.
  • Roa Chamorro R; Endocrinology and Nutrition Department, Hospital Universitario Virgen Macarena, Sevilla, Spain.
  • Jaen Aguila F; Endocrinology and Nutrition Department, Hospital General Universitario de Alicante, Alicante, Spain.
  • Moya Mateo EM; Endocrinology and Nutrition Department, Hospital Joan XXIII, Tarragona, Spain.
  • Hanzu FA; Endocrinology and Nutrition Department, Hospital La Fé, Valencia, Spain.
  • Araujo-Castro M; Internal Medicine Department, Hospital Universitario Virgen de las Nieves, Granada, Spain.
High Blood Press Cardiovasc Prev ; 31(1): 43-53, 2024 Jan.
Article in En | MEDLINE | ID: mdl-38225508
ABSTRACT

INTRODUCTION:

Primary aldosteronism (PA) is associated with several cardiometabolic comorbidities. Specific treatment by mineralocorticoid receptor antagonists (MRA) or adrenalectomy has been reported to reduce the cardiometabolic risk. However, the cardiovascular benefit could depend on plasma renin levels in patients on MRA.

AIM:

To compare the development of cardiovascular, renal and metabolic complications between medically treated patients with PA and those who underwent adrenalectomy, taking the renin status during MRA treatment into account.

METHODS:

A multicenter retrospective study (SPAIN-ALDO Register) of patients with PA treated at 35 Spanish tertiary hospitals. Patients on MRA were divided into two groups based on renin suppression (n = 90) or non-suppression (n = 70). Both groups were also compared to unilateral PA patients (n = 275) who achieved biochemical cure with adrenalectomy.

RESULTS:

Adrenalectomized patients were younger, had higher plasma aldosterone concentration, and lower potassium levels than MRA group. Patients on MRA had similar baseline characteristics when stratified into treatment groups with suppressed and unsuppressed renin. 97 (55.1%) of 176 patients without comorbidities at diagnosis, developed at least one comorbidity during follow-up (median 12 months vs. 12.5 months' follow-up after starting MRA and surgery, respectively). Surgery group had a lower risk of developing new cardiovascular events (HR 0.40 [95% CI 0.18-0.90]) than MRA group. Surgical treatment improved glycemic and blood pressure control, increased serum potassium levels, and required fewer antihypertensive drugs than medical treatment. However, there were no differences in the cardiometabolic profile or the incidence of new comorbidities between the groups with suppressed and unsuppressed renin levels (HR 0.95 [95% CI 0.52-1.73]).

CONCLUSION:

Cardiovascular, renal, and metabolic events were comparable in MRA patients with unsuppressed and suppressed renin. Effective surgical treatment of PA was associated with a decreased incidence of new cardiovascular events when compared to MRA therapy.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Cardiovascular Diseases / Hyperaldosteronism / Hypertension Type of study: Clinical_trials / Diagnostic_studies / Observational_studies / Risk_factors_studies Limits: Humans Country/Region as subject: Europa Language: En Journal: High Blood Press Cardiovasc Prev Year: 2024 Document type: Article Affiliation country: Country of publication:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Cardiovascular Diseases / Hyperaldosteronism / Hypertension Type of study: Clinical_trials / Diagnostic_studies / Observational_studies / Risk_factors_studies Limits: Humans Country/Region as subject: Europa Language: En Journal: High Blood Press Cardiovasc Prev Year: 2024 Document type: Article Affiliation country: Country of publication: